On Dec. 1, a judge in the U.S. District Court for the District of Delaware granted Natera Inc. a permanent injunction in its patent infringement suit against Archerdx Inc. and its former parent company, Invitae Corp., adding another block to the intellectual property wall of protection around the market dominance of Signatera, Natera’s molecular residual disease (MRD) assay. Read More
Using minimally invasive focal therapies to treat prostate cancer are much more cost-effective and can improve patients’ quality of life compared to surgery or radiotherapy, according to a study published in the Journal of Medical Economics. Read More
Spark Biomedical Inc. is seeking patent protection for the use of its transcutaneous auricular neurostimulation (tAN) platform for treating stress and improving performance in stressful situations while controlling bleeding.
One of the difficulties for preventing the evolution of a tumor is that cancer progression can be promoted by undifferentiated or migrating cells whose states could follow different directions. At the 40th edition of Barcelona Biomed conferences at the Institute for Research in Biomedicine (IRB Barcelona), which took place from Nov. 27 to 29, 2023, and is entitled “Cancer in Context: Cellular, Tissue, and Organismal Determinants of Malignant Fates,” Angela Nieto presented her latest data on epithelial-to-mesenchymal transition (EMT). Read More
Now, in addition to the daily news lineup, you can create topic alerts to be delivered directly to your inbox or via an RSS reader. It’s easy to set up!
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Apogepha Arzneimittel, Benchmark Electronics, Guardant, Nanovibronix, Personalis, Titan Medical. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Neuronetics. Read More
